Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating when Labcorp’s diagnostics volumes jump, or spotting CMS reimbursement risks buried in a footnote, usually means scrolling through hundreds of dense pages. Investors also juggle separate documents to track drug-development backlog, litigation updates, and Labcorp insider trading Form 4 transactions — a time-consuming process.
Stock Titan solves that problem. Our AI reviews every Labcorp quarterly earnings report 10-Q filing, flags segment revenue shifts, and delivers plain-English summaries within minutes. Need real-time alerts? We stream Labcorp Form 4 insider transactions real-time so you never miss an executive’s move. From Labcorp SEC filings explained simply to detailed Labcorp earnings report filing analysis, our tools answer natural questions such as “How to read Labcorp’s 10-K?” or “What did management disclose in the latest 8-K?”
Here’s what you can explore today:
- Labcorp annual report 10-K simplified – AI-powered breakdown of diagnostics vs. drug-development margins.
- Labcorp 8-K material events explained – instant context on acquisitions, subpoenas, or changes in payer policy.
- Labcorp executive stock transactions Form 4 – monitor patterns before earnings releases.
- Labcorp proxy statement executive compensation – compare leadership pay with testing-volume performance.
Whether you’re understanding Labcorp SEC documents with AI for compliance, or scanning trendlines for your next investment thesis, Stock Titan provides:
- AI-powered summaries that demystify accounting jargon
- Real-time EDGAR updates across all forms
- Expert insights into diagnostics pricing, payer mix, and backlog shifts
Stop hunting through PDFs and start making decisions with clarity.
Sandra D. van der Vaart, identified as EVP, Chief Legal Officer of Labcorp Holdings Inc. (LH), reported offsetting option exercise and share sale transactions dated 08/13/2025. She exercised 3,903 non-qualified stock options with an exercise price of $131.43 per share, resulting in the acquisition of 3,903 common shares. On the same date she sold 3,903 common shares at a reported price of $271.4249 per share. The filing shows 6,176.6691 shares beneficially owned after the acquisition line and 2,273.6691 shares after the sale line. The options were granted under the company omnibus plan, vesting began 02/12/2020 and are exercisable through 02/11/2029. An additional 30.1294 shares were included from the employee stock purchase plan.
Labcorp Holdings Inc. (LH) filed a Form 144 reporting a proposed sale of 3,903 shares of common stock with an aggregate market value of $1,059,371.39. The filing lists 83,100,000 shares outstanding and names Fidelity Brokerage Services as the broker; the sale is slated for 08/13/2025 on the NYSE.
The filing shows the securities were acquired via an option granted on 02/12/2019, with acquisition and payment dated 08/13/2025, and payment made in cash. It also reports no securities sold in the past three months for the selling person and includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Adam H. Schechter, President & CEO and Director of Labcorp Holdings Inc. (LH), reported a sale of company common stock on 08/11/2025. The Form 4 discloses that 5,643 shares were disposed of at a reported price of $266.78 per share pursuant to a plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The filing was executed by an attorney-in-fact on 08/13/2025.
After the reported transaction Schechter beneficially owns 93,319 shares directly. No derivative transactions are reported on this Form 4. The disclosure identifies the transaction code as an S-sale under the stated 10b5-1 plan.
Labcorp Holdings Inc. insider notice reports a proposed sale of 5,643 common shares for an aggregate market value of $1,505,439.54, to be executed through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/11/2025. The shares were acquired on 03/30/2023 by restricted stock vesting as compensation. The filing also shows the seller previously sold 6,105 shares on 05/12/2025 for gross proceeds of $1,518,496.65. The issuer's total outstanding common shares are reported as 83,100,000. By signing, the seller represents no undisclosed material adverse information and notes the compliance statements relevant to Rule 144 and Rule 10b5-1.
Labcorp Holdings (LH) – insider sale by finance executive
Form 4 filed 07/31/2025 details that SVP & Chief Accounting Officer Peter J. Wilkinson sold a total of 202 common shares on 07/29/2025 in two open-market transactions: 102 shares at $261.0102 and 100 shares at $261.035. Estimated gross proceeds equal roughly $52.7 k. Following the sales, Wilkinson’s direct ownership fell to 1,852.2194 shares. No derivative securities were reported.
The activity modestly reduces the executive’s stake and is immaterial relative to Labcorp’s share count, though investors may note it when tracking insider sentiment.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
